Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Madrigal Pharmaceuticals, Inc. (MDGL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company focused on MASH, Madrigal uses SEC reports to present detailed information on its financial performance, capital structure, risk factors, and material corporate events related to Rezdiffra (resmetirom) and its broader pipeline.
Investors can review current reports on Form 8-K where Madrigal announces quarterly and annual financial results, material financing arrangements, licensing agreements, and other significant events. Recent 8-K filings describe quarterly earnings releases, a senior secured credit facility with funds managed by Blue Owl Capital, and the use of proceeds to repay and terminate a prior loan agreement, as well as shareholder voting results from the annual meeting.
In addition to 8-Ks, users can access Madrigal’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) to study revenue from Rezdiffra, research and development spending on the MAESTRO clinical program and pipeline assets such as the licensed oral GLP-1 receptor agonist and ervogastat, and detailed risk factor disclosures. These filings also discuss regulatory considerations around MASH indications, ongoing Phase 3 outcomes trials, and forward-looking statements about the company’s strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from long filings, helping readers quickly understand changes in liquidity, debt covenants, operating expenses, and other important metrics without reading every page. Users can also track executive and director-related disclosures when Forms 3, 4, and 5 appear in the SEC stream, providing visibility into equity awards and other reportable transactions.
By combining real-time EDGAR updates with AI-generated insights, this page offers a practical way to follow how Madrigal’s clinical progress in MASH, commercialization of Rezdiffra, and financing decisions are reflected in its official SEC reporting.
Madrigal Pharmaceuticals director Paul A. Friedman reported an option exercise and small share sale. On January 9, 2026, he exercised a stock option for 280 shares of common stock at $15.80 per share, then sold 280 shares of common stock at a weighted average price of $551.2414 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025.
After these transactions, he directly owned 187,164 shares of Madrigal common stock. The filing also notes 655,540 shares held indirectly through SQN LLC, an entity for which he and his spouse are managing members, with a disclaimer that he only benefits to the extent of his pecuniary interest.
Madrigal Pharmaceuticals director Paul A. Friedman reported insider transactions in company common stock. On January 9, 2026, he exercised a fully vested stock option for 24,520 shares of common stock at an exercise price of $15.8 per share and then sold multiple small blocks of common stock the same day under a Rule 10b5-1 trading plan adopted on September 10, 2025. The reported sale prices are disclosed as weighted averages, with underlying trades occurring at prices generally ranging from about $511.71 to $545.79 per share. After these transactions, he directly held 187,164 shares of common stock and 280 stock options, and also reported 655,540 shares held indirectly through SQN LLC, for which he and his spouse are managing members.
Madrigal Pharmaceuticals director Rebecca Taub reported stock transactions dated 01/09/2026. She exercised a stock option for 240 shares of common stock at $15.80 per share and then sold 40 shares at $545.79 and 200 shares at a weighted average price of $551.242. These sales were made under a Rule 10b5-1 trading plan adopted on September 10, 2025. After the reported sales, she directly owned 455,589 shares of common stock. The filing also lists 655,540 shares held indirectly by SQN, LLC, an entity for which she and her spouse are managing members, and she disclaims beneficial ownership of those securities except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals director Rebecca Taub reported an insider transaction involving stock options and common shares of Madrigal Pharmaceuticals, Inc. (MDGL) dated 01/09/2026. She exercised a stock option for 18,410 shares of common stock at an exercise price of
On the same date, she then sold Madrigal common stock in numerous open-market transactions under a Rule 10b5-1 trading plan, at weighted-average prices disclosed in ranges from
MDGL filed a Rule 144 notice covering the planned sale of 18650 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ.
These shares were acquired on 01/09/2026 by exercising stock options for cash and have an aggregate market value of 10373503.00. The issuer reports 22711420 shares outstanding. In the past three months, 10b5-1 sales disclosed include 18650 shares for Rebecca A Taub with gross proceeds of 10297573.26 and 24800 shares for Paul A Friedman with gross proceeds of 13694158.24.
Madrigal Pharmaceuticals disclosed an insider transaction by a company director on December 10, 2025. The director acquired 24,800 shares of common stock at $15.8 per share and, on the same day, sold 24,800 shares in multiple open-market trades at weighted average prices described in several ranges between approximately $547 and $555, all under a Rule 10b5-1 trading plan adopted on September 10, 2025.
After these transactions, the director beneficially owned 187,164 shares directly and 655,540 shares indirectly through SQN LLC, where the director and spouse are managing members and disclaim beneficial ownership beyond any pecuniary interest.
Madrigal Pharmaceuticals director reported several stock transactions dated 12/10/2025. The reporting person exercised a stock option to acquire 18,650 shares of common stock at $15.8 per share, then sold multiple blocks of shares the same day under a Rule 10b5-1 trading plan adopted on September 10, 2025 at weighted-average prices reported between $547.16 and $555.31 per share, plus an additional sale at $555.39 per share.
The reporting person also made a charitable contribution of 5,455 shares of common stock to a donor advised fund. After these transactions, they held 455,589 shares directly and 655,540 shares indirectly through SQN LLC, where the reporting person and a spouse are managing members, with beneficial ownership of those indirect shares disclaimed except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals (MDGL) reported that its Chief Commercial Officer filed a Form 4 disclosing multiple sales of common stock on 11/21/2025. One sale of 894 shares was made by the company on the officer’s behalf to cover tax withholding tied to vesting of restricted stock units and was automatic, not at the officer’s discretion. Additional market sales were executed the same day in small blocks under a Rule 10b5-1 trading plan adopted on November 5, 2024, at weighted average prices generally between about $547 and $565 per share. Following these transactions, the officer directly beneficially owned 10,032 shares of Madrigal common stock.
Madrigal Pharmaceuticals (MDGL) reported insider activity by a director on 11/13/2025. The filing shows two option exercises and subsequent open‑market sales executed under a Rule 10b5‑1 trading plan adopted on August 14, 2025.
The director exercised stock options for 2,500 shares at an exercise price of $7.36 and 6,000 shares at $16.46. Following the exercises, multiple sales occurred the same day across several tranches at weighted average prices, with disclosed ranges from $514.03 to $528.94 per share. After these transactions, the filing lists 21,197 shares of common stock beneficially owned on a direct basis.
The option entries indicate the underlying shares were fully vested and exercisable. Price footnotes state each reported sale price is a weighted average, with full trade‑level details available upon request.
Madrigal Pharmaceuticals (MDGL) director reported option exercises and share sales. On 11/05/2025, the insider exercised stock options for 5,470 shares at $9.45, 10,000 shares at $303.79, and 1,105 shares at $280.04 (all fully vested). The insider then sold multiple blocks of common stock, with weighted-average sale prices ranging from about $480.2397 to $490.9817, as detailed in footnotes. After these transactions, the insider directly beneficially owned 2,627 shares.